IPO - Profile

Summary

Heart disease is the leading cause of death in the world, accounting for more deaths than from all cancers combined. In the United States, more than 30 million adults are diagnosed with heart disease and approximately 35,000 children are born each year with congenital heart disease (CHD). There are over 250 known genetically defined disorders where the primary source of morbidity and mortality involves the heart, but there are few approved products that target the underlying cause of such diseases. Recent analysis has shown that mortality rates due to heart More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 12,000,000 Positive High 17.05%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jul, 2021

Offer 30 Jul, 2021

Look Ahead

Lock Up Expiry Jan 30, 2022

IPO Terms

Offer Price $15.00
Offer Size 12M

Market Sentiments

Stock Price